Nancy J. Hutson - Aug 18, 2021 Form 4/A - Amendment Insider Report for PhaseBio Pharmaceuticals Inc (PHASQ)

Role: Director
Signature: /s/ John P. Sharp, Attorney-in-fact
Stock symbol: PHASQ
Transactions as of: Aug 18, 2021
Transactions value $: $9,240
Form type: 4/A - Amendment
Date filed: 5/20/2022, 04:47 PM
Date Of Original Report: Aug 19, 2021
Previous filing: Aug 17, 2021
Next filing: Oct 19, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHASQ	Common Stock	Purchase	$9.24K	+3K	+300%	$3.08^*	4K	Aug 18, 2021	Held in an individual retirement account for the benefit of the Reporting Person	F1
holding	PHASQ	Common Stock						33.8K	Aug 18, 2021	Direct	F2

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
F2	Amended to report direct share ownership.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Amended to report direct share ownership.